IP Library › Granted Patent US 12,383,621
Granted Patent B2
US 12,383,621 · App. 17/306,167 · Granted Aug 12, 2025

Pharmaceutical compositions comprising POH derivatives

Inventors: Thomas Chen (La Canada, CA); Daniel Levin (La Canada, CA); Satish Puppali (Rancho Cucamonga, CA)
Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
A61K45/06A61K9/0043A61K31/4015A61K31/415A61K47/54A61K47/55C07D207/26C07D231/12C07D487/04A61N5/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,621
App. No.
17/306,167
Granted
Aug 12, 2025
Kind
B2
Abstract

The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.

Claims (5)

1. A method for treating a cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of perillyl alcohol carbamate using a nasal delivery device, wherein the perillyl alcohol carbamate comprises perillyl alcohol conjugated with rolipram, wherein the cancer is a tumor of the nervous system.

2. The method of claim 1 , wherein the nasal delivery device is selected from the group consisting of an intranasal inhaler, an intranasal spray device, an atomizer, a nebulizer, a metered dose inhaler (MDI), a pressurized dose inhaler, an insufflator, a unit dose container, a pump, a dropper, a nasal spray bottle, a squeeze bottle and a bi-directional device.

3. The method of claim 1 , wherein the tumor is a glioblastoma.

4. The method of claim 1 , further comprising the step of treating the mammal with radiation.

5. The method of claim 1 , further comprising the step of delivering to the mammal a chemotherapeutic agent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2023
From: NEONC TECHNOLOGIES INC.
To: UNIVERSITY OF SOUTHERN CALIFORNIA
Reel/Frame 063726/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2023
From: CHEN, THOMAS; LEVIN, DANIEL; PUPPALI, SATISH
To: NEONC TECHNOLOGIES, INC.
Reel/Frame 062430/0948 →
Continuity (8)
Continuation 16388535 · Apr 18, 2019
Continuation 14595865 · Jan 13, 2015
Continuation In Part 14455293 · Aug 8, 2014
Continuation 13566731 · Aug 3, 2012
Continuation PCTUS2011049392 · Aug 26, 2011
Provisional Application 61471402 · Apr 4, 2011
Provisional Application 61377747 · Aug 27, 2010
Related Publication 20210268108A1 · Sep 2, 2021
References Cited (224)
US 3957856A · Ansari · 1976 [cited by applicant]
US 4272441A · Keay · 1981 [cited by applicant]
US 4353365A · Hallworth · 1982 [cited by applicant]
US 4524769A · Wetterlin · 1985 [cited by applicant]
US 4738851A · Schoenwald · 1988 [cited by applicant]
US 4882150A · Kaufman · 1989 [cited by applicant]
US 5035237A · Newell · 1991 [cited by applicant]
US 5077033A · Viegas · 1991 [cited by applicant]
US 5225183A · Purewal · 1993 [cited by applicant]
US 5239993A · Evans · 1993 [cited by applicant]
US 5403841A · Lang · 1995 [cited by applicant]
US 5415162A · Casper · 1995 [cited by applicant]
US 5521222A · Ali · 1996 [cited by applicant]
US 5587402A · Gould · 1996 [cited by applicant]
US 5602184A · Myers · 1997 [cited by applicant]
US 5698219A · Valdivia · 1997 [cited by applicant]
US 5715810A · Armstrong · 1998 [cited by applicant]
US 5776445A · Cohen · 1998 [cited by applicant]
US 5800807A · Hu · 1998 [cited by applicant]
US 5874063A · Briggner · 1999 [cited by applicant]
US 5983956A · Trofast · 1999 [cited by applicant]
US 5994598A · Chastain · 1999 [cited by applicant]
US 6006745A · Marecki · 1999 [cited by applicant]
US 6056950A · Saettone · 2000 [cited by applicant]
US 6123068A · Lloyd · 2000 [cited by applicant]
US 6133324A · Imagawa · 2000 [cited by applicant]
US 6143227A · Heiden · 2000 [cited by applicant]
US 6197934B1 · DeVore · 2001 [cited by applicant]
US 6221398B1 · Jakupovic · 2001 [cited by applicant]
US 6261547B1 · Bawa · 2001 [cited by applicant]
US 6268533B1 · Gao · 2001 [cited by applicant]
US 6313176B1 · Ellinwood, Jr. · 2001 [cited by applicant]
US 6378519B1 · Davies · 2002 [cited by applicant]
US 7015349B2 · Jardien · 2006 [cited by applicant]
US 7056491B2 · Gould · 2006 [cited by applicant]
US 7563768B2 · Nakamura · 2009 [cited by applicant]
US 7568480B2 · Foley · 2009 [cited by applicant]
US 7601355B2 · Howard · 2009 [cited by applicant]
US 7638549B2 · Coleman · 2009 [cited by applicant]
US 7745670B2 · DiMauro · 2010 [cited by applicant]
US 7816398B2 · Swindell · 2010 [cited by applicant]
US 8058469B2 · Belfadhel · 2011 [cited by applicant]
US 8084454B2 · Kawabe · 2011 [cited by applicant]
US 8236862B2 · Chen · 2012 [cited by applicant]
US 8507734B2 · Chen · 2013 [cited by applicant]
US 8642543B2 · Tezapsidis · 2014 [cited by applicant]
US 8916545B2 · Chen · 2014 [cited by applicant]
US 9499461B2 · Chen · 2016 [cited by examiner]
US 9663428B2 · Chen · 2017 [cited by applicant]
US 9913838B2 · Chen · 2018 [cited by applicant]
US 9987237B2 · Chen · 2018 [cited by applicant]
US 11013804B2 · Chen · 2021 [cited by examiner]
US 11077104B2 · Chen · 2021 [cited by examiner]
US 11147809B2 · Chen · 2021 [cited by examiner]
US 20020010128A1 · Parks et al. · 2002 [cited by applicant]
US 20020137799A1 · Gould · 2002 [cited by applicant]
US 20020177609A1 · Swindell · 2002 [cited by examiner]
US 20040087651A1 · Pereira Da Fonseca · 2004 [cited by applicant]
US 20040192778A1 · Jardien · 2004 [cited by applicant]
US 20050250854A1 · Li · 2005 [cited by applicant]
US 20060014732A1 · Hofmann · 2006 [cited by applicant]
US 20060029586A1 · Chen · 2006 [cited by applicant]
US 20060104997A1 · Constantinides · 2006 [cited by applicant]
US 20080275057A1 · Kawabe · 2008 [cited by applicant]
US 20080319039A1 · Bersch · 2008 [cited by applicant]
US 20090031455A1 · Aharoni · 2009 [cited by applicant]
US 20090281522A1 · Thio · 2009 [cited by applicant]
US 20090291894A1 · Tezapsidis · 2009 [cited by applicant]
US 20090317377A1 · Yeomans · 2009 [cited by applicant]
US 20090326275A1 · DiMauro · 2009 [cited by applicant]
US 20090328239A1 · Brauner · 2009 [cited by applicant]
US 20100113780A1 · Kuroita · 2010 [cited by applicant]
US 20100113819A1 · Belfadhel · 2010 [cited by applicant]
US 20100168228A1 · Bose · 2010 [cited by applicant]
US 20100226913A1 · Chen · 2010 [cited by applicant]
US 20100305214A1 · D'Alessio · 2010 [cited by applicant]
US 20120184560A1 · Wong · 2012 [cited by applicant]
US 20120219541A1 · Chen et al. · 2012 [cited by applicant]
US 20130203828A1 · Chen · 2013 [cited by applicant]
US 20130210877A1 · Chen et al. · 2013 [cited by applicant]
US 20130331422A1 · Chen · 2013 [cited by applicant]
US 20140235631A1 · Bunt · 2014 [cited by applicant]
US 20140364471A1 · Chen · 2014 [cited by applicant]
US 20140364472A1 · Chen · 2014 [cited by applicant]
US 20170190710A1 · Chen et al. · 2017 [cited by applicant]
US 20170369408A1 · Chen et al. · 2017 [cited by applicant]
US 20210244820A1 · Chen · 2021 [cited by applicant]
US 20210283127A1 · Chen · 2021 [cited by applicant]
US 20220096464A1 · Chen · 2022 [cited by applicant]
US 20220133712A1 · Chen · 2022 [cited by applicant]
US 20230405125A1 · Chen · 2023 [cited by examiner]
US 20240016800A1 · Chen · 2024 [cited by applicant]
CN 101584660 · 2009 [cited by applicant]
CN 101854925 · 2010 [cited by applicant]
CN 102405044 · 2012 [cited by applicant]
CN 103168018A · 2013 [cited by applicant]
CN 103517892B · 2016 [cited by applicant]
EP 0717987A2 · 1996 [cited by applicant]
EP 1142868 · 2001 [cited by applicant]
EP 1236802 · 2002 [cited by applicant]
EP 2609064A2 · 2013 [cited by applicant]
JP H0748264 · 1995 [cited by applicant]
JP H09509151 · 1997 [cited by applicant]
JP H09510446 · 1997 [cited by applicant]
JP 2000501376 · 2000 [cited by applicant]
JP 2004529125 · 2004 [cited by applicant]
JP 2004534520 · 2004 [cited by applicant]
JP 2005518354 · 2005 [cited by applicant]
JP 2007048264A · 2007 [cited by applicant]
JP 2007527411 · 2007 [cited by applicant]
JP 2007529414 · 2007 [cited by applicant]
JP 2008535928 · 2008 [cited by applicant]
JP 2009502888 · 2009 [cited by applicant]
JP 2009510171 · 2009 [cited by applicant]
JP 2010065038 · 2010 [cited by applicant]
JP 2010520216 · 2010 [cited by applicant]
JP 5797755 · 2015 [cited by applicant]
JP 5982507 · 2016 [cited by applicant]
JP 6122564 · 2017 [cited by applicant]
JP 6431009 · 2018 [cited by applicant]
WO 9222286 · 1992 [cited by applicant]
WO 9520567 · 1995 [cited by applicant]
WO 9712687 · 1997 [cited by applicant]
WO 9953901A1 · 1999 [cited by applicant]
WO 9955319 · 1999 [cited by applicant]
WO 0030614 · 2000 [cited by applicant]
WO 0037434 · 2000 [cited by applicant]
WO 0061108A1 · 2000 [cited by applicant]
WO 02066662 · 2002 [cited by applicant]
WO 02098399A2 · 2002 [cited by applicant]
WO 03043657 · 2003 [cited by applicant]
WO 03057193A1 · 2003 [cited by applicant]
WO 2004076400A1 · 2004 [cited by applicant]
WO 2004101605 · 2004 [cited by applicant]
WO 2005039496 · 2005 [cited by applicant]
WO 2006110882 · 2006 [cited by applicant]
WO 2007014925 · 2007 [cited by applicant]
WO 2007041637 · 2007 [cited by applicant]
WO 2008109333 · 2008 [cited by applicant]
WO 2009040420A2 · 2009 [cited by applicant]
WO 2010091198A1 · 2010 [cited by applicant]
WO 2010115491 · 2010 [cited by applicant]
WO 2011109635 · 2011 [cited by applicant]
WO 2012027693A2 · 2012 [cited by applicant]
WO 2012083178 · 2012 [cited by applicant]
WO 2016040656 · 2016 [cited by applicant]
WO 2016130800A2 · 2016 [cited by applicant]
Goldhoff, Patricia, et al. “Targeted Inhibition of Cyclic AMP Phosphodiesterase-4 Promotes Brain Tumor Regression.” Clinical Cancer Research, vol. 14, No. 23, Dec. 2008, pp. 7717-7725. DOI.org (Crossref), https://doi.or… [cited by examiner]
Liu et al., “Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells”, vol. 4, (Jan. 1, 2001), pp. 81-91, URL: http://www.nature.com/pcan/journal/v4/n2/pdf/4500506a.pd… [cited by applicant]
Vasso Skouridou et al, “Use of essential oils as media for the enantioselective esterification of the monoterpene perillyl alcohol catalyzed by lipase”, European Journal of Lipid Science and Technology., DE, (Apr. 1, 20… [cited by applicant]
Da Fonseca et al., Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma , J Cancer Res Clini Oncol (2011) ; 137(2):287-93 (§) DOI: 10.1007/s00432-010-0873-0. [cited by applicant]
Hee-Yeon Cho et al : “ATPS-07NE0214 Rolipram Conjugated to Peri LL YL Alcohol is a Novel Drug Cytotoxic for Gliomas by Targeting the Death Receptor Mediated Trail Pathway”, Neuro-Oncology, vol. 17, No. suppl 5, Nov. 9, … [cited by applicant]
Extended European Search Report of corresponding EP 19818648.8, dated Mar. 1, 2022. [cited by applicant]
Addeo et al. (Cancer (2008) vol. 112 pp. 2524-2531). [cited by applicant]
Allavena et al.(Current Opinion in Genetics & Development 2008, 18:3-10) (Year: 2008). [cited by applicant]
Astro, Skin-cancer-brochure, 2007 (Year: 2007) [2 pages]. [cited by applicant]
B. Brennan, Nasopharyngeal carcinoma, Orphanet J Rare Dis 1 (2006) 23. [cited by applicant]
Balassiano et al. Intern J. Mol. Med (2002) 10:785-788. [cited by applicant]
Behan et al (Curr. Treat. Options in Oncol., 2016; 17:60, pp. 1-17) (Year: 2016). [cited by applicant]
Bhosle et al. Indian Journal of Pharmaceutical Sciences 2006, May-June, p. 286-294. [cited by applicant]
Braun et al. Treatment if glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry. Drug, Design, Development and Therapy (2008), vol. 2pp. 289-301. [cited by applicant]
Cancer Lett. Mar. 2, 20118; 302(2):100-8. [cited by applicant]
Chen et al. Inhalational temozolomide- a new mode of treating malignant gliomas. Proceedings of the 103rd Annual1 Meeting of the American Association for Cancer Research 2012, Cancer Res. 72(8 Suppl): Abstract No. 3893,… [cited by applicant]
Chen, et al., “A novel temozolomide analog, NE0212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo”, Cancer Letters (Mar. 2015), 358(2) 144-51. [cited by applicant]
Chen, et al. “Synthesis of Deuterium Labeled Perillyl Alcohol and Dual C-13 and Deuterium Labeled Perillic Acid, Major Metabolism of d-Limonene” Journal—Dec. 31, 1996, 9 pages, vol. XXXIX, No. 5 Journal of Labelled Comp… [cited by applicant]
Chen; et al., “The Type IV Phosphodiesterase Inhibitor Rolipram Induces Expression Inhibitors p21Cip1 and p27Kip1, Resulting in Growth Inhibition, Increased Differentiation, and Subsequent Apoptosis of Malignant A-172 G… [cited by applicant]
Chen; et al., “Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models”, Cancer Lett. (Mar. 2011 ), 302(2): 100-8. [cited by applicant]
Cho et al., “NE0212, Temozolomide Conjugated to Perillyl Alcohol, is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas.”, MOL.. Cancer Ther., vol. 13, No. 8, (2014), pp. 2004-2017, … [cited by applicant]
Crespi et al. (1986) Biochem. Biophys. Res. Commun. 136(2):521-8. [cited by applicant]
Crow; et al., “Inhibition of topoisomerase I by anthracycline antibiotics: evidence for general inhibition of topoisomerase | by DNA-binding agents”, J. Med. Chem. (1994), 37(19): 3191-3194. [cited by applicant]
Da Fonseca et al. Arch. Immunol Ther. Exp. (2008) 56: 267-276. [cited by applicant]
Da Fonseca et al. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas (2008) Surgical Neurology 70:259-267. [cited by applicant]
Das et al. Design and synthesis of potential new apoptosis agents: hybrid compounds containing perillyl alcohol and new constrained retinoids. Tetrahedron Letters 2010, 51, 1462-1466. [cited by applicant]
Deepika Rajesh: “Perillyl Alcohol as a Radio-/Chemosensitizer in Malignant Glioma”: The Journal of Biological Chemistry, 2003, vol. 278, No. 38, pp. 35968-35978. [cited by applicant]
Denny et al. “Dual topoisomerase I/II inhibitors in cancer therapy” (2003) Curr. Top. Med. Chem. 3(3):339-353. [cited by applicant]
Downward, “Targeting RAS signaling pathways in cancer therapy”, Nat. Rev. Cancer (Jan. 2003), 3(1):11-22. [cited by applicant]
El Houssamea et al., “Palladium-catalyzed alkoxycarbonylation of allylic natural terpenic functionalized olefins” Laboratoire de Catalyse de Lille, UPRESA CNRS 8010, ENSC Lille BP 108, 59652 Villeneuve d?Ascq, France, a… [cited by applicant]
Encyclopedia of Chemical Technology, Fourth Edition, vol. 23, p. 834-8351997. [cited by applicant]
Fernandes et al. Perillyl alcohol induces apoptosis in human glioblastoma multiforme cells. Oncol. Rep. (2005) vol. 13 pp. 943-947. [cited by applicant]
Foglesong et al. (1992) Cancer Chemother. Pharmacol. 30(2): 123-125. [cited by applicant]
Gatto et al. “Identification of Topoisomerase I as the Cytotoxic Target of the Protoberberine Alkaloid Coralyne” (1996) Cancer Res. 15 (12):2795-2800. [cited by applicant]
Gonda (1990) Critical Reviews in Therapeutic Drug Carrier Systems 6:273-313. [cited by applicant]
Goodsell, et al., “The Molecular Perspective The ras Oncogene” Oncologist (1999), 4(3) 263-264. [cited by applicant]
GouldM. Cancer chemoprevention and therapy by monoterpenes. Environ Health Perspect. Jun. 1997; 105 (Suppl 4): 977-979. [cited by applicant]
Hashizume et al. (2008) Neuroncology 10:112-120. [cited by applicant]
Healthcommunities. Nervous System Tumors [online] [Retrieved on Feb. 19, 2016] Retrieved from the internet: <URL:http://www.healthcommunities.com/nervous-system-tumors/treatment-chemotherapy.shtml>. [cited by applicant]
Healthcommunities.com [online] Retrieved on Feb. 2, 2017 Retrieved from the internet kurl:http://www. healthcommunities.com/nervous-system-tumors/other-treatment.shtml>. [cited by applicant]
Healthcommunities.com. Nervous System Tumors [online] [Retrieved on Jul. 22, 2017] Retrieved from the internet: URL :< http://www.healthcommunities.com/nervous-system-tumors/other-treatment.shtml>. [cited by applicant]
Henry et al., A Pharmacokinetic study of midazolam in dogs: nasal drop vs. atomizer administration, Pediatric Dentistry (1998), 20(5) 321-326. [cited by applicant]
J. of Immunological Methods 65: 55 63, 1983. [cited by applicant]
J. Tsang et al., Novel Therapy for nasopharyngeal carcinoma-where are we. Oral Oncol. 50 (2014) 798-801. [cited by applicant]
Kardosh; et al., “Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib”, Blood (Aug. 2005), 106:4330-4338. [cited by applicant]
Kummar et al. British Journal of Clinical Pharmacology 2006, 62 (1), 15-26. [cited by applicant]
Kushner et al. 'Pharmacological uses and perspectives of heavy water and deuterated compounds'Canadian Journal of Physiology and Pharmacology, 77(2), p. 79-88, 1999. [cited by applicant]
L. Jang-Chun et al., Comparisons of quality of life for patients with nasopharyngeal carcinoma after treatment with different RT technologies, Acta Otorhinolaryngol Ital 34 (2014) 241-246. [cited by applicant]
Li et al. Protoberberine alkaloids and derivatives thereof including berberrubine and coralyne. Biochemistry. (2000) 39 (24):7107-7116. [cited by applicant]
Lin et al., Characterization of seven newly established nasopharyngeal carcinoma cell lines, Lab Invest 68 (1993) 716-727. [cited by applicant]
Lluria-Prevatt et al.(Cancer Epidemiology, Biomarkers & Prevention, vol. 11, 573-579, Jun. 2002) (Year: 2002). [cited by applicant]
Louis et al. Acta Neuropathol. 2007, 114, 97-109. [cited by applicant]
Makhey et al. “Substitute Benzo[i]phenanthridines as Mammalian Topoisomerase-Targeting Agents” (2003) Bioorg. Med. Chem. 11 (8): 1809-1820. [cited by applicant]
McKeage et al. “Phase I and Pharmacokinetic Study of an Oral Platinum Complex Given Daily for 5 Days in Patients with Cancer” (1997) J. Clin. Oncol. Vol. 15, p. 2691-2700. [cited by applicant]
Meyskens F L Jr et al., “Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent”, Clinical Cancer Research, the American Association for Cancer Research, US, (May 30, 1999), vol. 5, ISSN 1078-0432, pp.… [cited by applicant]
Minitti et al. Anticancer Res. 2009, 29 (12), 5171-5185. [cited by applicant]
Otagirt, Masaki, Prodrug, New Drug Delivery System, CMC Co., Ltd. Shima Kentaro. 2000. p. 123-126. [cited by applicant]
Papamicheal (1999) The Oncologist 4:478-487. [cited by applicant]
Pommier, Y. “Topoisomerase I inhibitors: camptothecins and beyond” Nat Rev Cancer. Oct. 2006;6(10):789-802. [cited by applicant]
Progenitor cells and glioma formation) Cur. Open. Neurology, 2001, 14: 683-688 (Year: 2001). [cited by applicant]
Raeburn et al. Pharmacol Toxicol Methods (1992) 27:143-159. [cited by applicant]
Recht et al. The New England Journal of Medicine (1996), vol. 334, pp. 1356-1361 (Year: 1996). [cited by applicant]
S.M. Cao, et al., The prevalence and prevention of nasopharyngeal carcinoma in China, Chin J Cancer 30 (2011) 114-119. [cited by applicant]
Schobert; et al., “Monoterpenes as Drug Shuttles: Cytotoxic (6-minomethylnicotinate) dichloridoplatinum(II) Complexes with Potential To Overcome Cisplatin Resistance”, J. Med. Chem. (2007), 50:1288-1293. [cited by applicant]
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, 1996 vol. 1, pp. 1004-1010. [cited by applicant]
Stupp et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England J Med. 352: 987-996, 2005. [cited by applicant]
Thorne, et al. (2004) Neuroscience 127:481-496. [cited by applicant]
Tung, “The Development of Deuterium-Containing Drugs”, Innovations in Pharmaceutical Technology (Mar. 2010), No. 32:24-26, 28. [cited by applicant]
Vogelstein et al. Cancer genes and the pathways they control. (2004) Nature Medicine, vol. 10, pp. 789-799. [cited by applicant]
Wei, et al. nasopharyngeal carcinoma. Lancet 365 (2005) 2041-2054. [cited by applicant]
Wen et al. Malignant gliomas in adults. New England J Med. 359: 492-507, 2008. [cited by applicant]
Wen, et al. Malignant Gliomas in Adults. New England Journal of Medicine. Jul. 31, 2008—359:492-507. [cited by applicant]
Wennerberg, et al., “The Ras superfamily at a glance”, Journal of Cell Science (Mar. 2005), 118(5) 843-6. [cited by applicant]
Wu et al., Nucleolin antisense oligodeoxynucleotides induce apoptosis and may be used as a potential drug for nasopharyngeal carcinoma therapy, Oncol. Rep. 27 (2012) 94-100. [cited by applicant]
Xu et al. “DNA Minor Groove Binding-Directed Poisoning of Human DNA Topoisomerase I by Terbenzimidazoles” (1998) Biochemistry 37(10):3558-3566. [cited by applicant]
Encyclopedia of Chemical Engineering, vol. 11, Chemical Industry Press, p. 228, Aug. 31, 1996. [cited by applicant]
The Practice of Medicinal Chemistry, updated version, 1st Edition, 1998, p. 297-333. [cited by applicant]